U.S. patent application number 10/550858 was filed with the patent office on 2006-11-09 for deodorant agent.
This patent application is currently assigned to Kao Corporation. Invention is credited to Syunichi Akiba, Katsutoshi Ara, Toyoki Hagura, Hiroshi Kusuoku.
Application Number | 20060251596 10/550858 |
Document ID | / |
Family ID | 33156818 |
Filed Date | 2006-11-09 |
United States Patent
Application |
20060251596 |
Kind Code |
A1 |
Akiba; Syunichi ; et
al. |
November 9, 2006 |
Deodorant agent
Abstract
This invention relates to deodorant agents, which contain ginkgo
or Phellodendron Bark or its extract as an active ingredient.
According to the present invention, deodorant agents which are high
in safety and can radically inhibit the emission of human body
malodors typified by sweat odor, especially, axillary odor.
Inventors: |
Akiba; Syunichi; (Tochigi,
JP) ; Ara; Katsutoshi; (Tochigi, JP) ;
Kusuoku; Hiroshi; (Tochigi, JP) ; Hagura; Toyoki;
(Tokyo, JP) |
Correspondence
Address: |
C. IRVIN MCCLELLAND;OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C.
1940 DUKE STREET
ALEXANDRIA
VA
22314
US
|
Assignee: |
Kao Corporation
14-10, Nihonbashikayabacho 1-chome
Tokyo
JP
103-8210
|
Family ID: |
33156818 |
Appl. No.: |
10/550858 |
Filed: |
September 19, 2003 |
PCT Filed: |
September 19, 2003 |
PCT NO: |
PCT/JP03/11982 |
371 Date: |
September 26, 2005 |
Current U.S.
Class: |
424/65 ; 424/752;
424/775 |
Current CPC
Class: |
A61Q 15/00 20130101;
A61K 8/9789 20170801; A61K 8/9771 20170801; A61K 36/756 20130101;
A61K 36/16 20130101; A61K 36/16 20130101; A61K 2300/00 20130101;
A61K 36/756 20130101; A61K 2300/00 20130101 |
Class at
Publication: |
424/065 ;
424/775; 424/752 |
International
Class: |
A61K 36/16 20060101
A61K036/16; A61K 8/97 20060101 A61K008/97; A61K 36/185 20060101
A61K036/185 |
Foreign Application Data
Date |
Code |
Application Number |
Apr 7, 2003 |
JP |
2003-103171 |
Claims
1. A deodorant agent comprising, as an active ingredient, ginkgo or
Phellodendron Bark or an extract thereof.
2. The deodorant agent according to claim 1, which inhibits a body
odor.
3. The deodorant agent according to claim 1, which inhibits sweat
odor.
4. The deodorant agent according to any one of claims 1-3, which
inhibits axillary malodor.
5. Use of ginkgo or Phellodendron Bark or an extract thereof for
the production of a deodorant agent.
6. A method for inhibiting a body odor, which comprises applying
ginkgo or Phellodendron Bark or an extract thereof to the skin.
Description
FIELD OF THE INVENTION
[0001] This invention relates to deodorant agents, which inhibit
the emission of human body malodors.
BACKGROUND OF THE INVENTION
[0002] Body odors are given off from all over the body, led by
sweat odor, (and including) bad breath, scalp odor, foot odor and
the like. Concerning sweat odor among these odors, it is composed
of an axillary odor typified by "hircismus" and an acid odor
emitted from all over the body. In recent years, there is an
increasing desire for the control of an axillary odor as a typical
example of odor that causes feeling of disgust.
[0003] In contrast to eccrine sweat glands, apocrine glands from
which sweat is secreted as a source of an axillary odor are
abundantly found at the axillae, the areolae, the pubes and the
like. They are not found spreading widely and localized in these
areas (for example, Pinkus H.; Mehregan A. H.; Adnexal Nevi and
Benign Adnexoid Tumors, in A Guide to Dermatohistopathlogy; 2nd
ed., pp 528, pp 29, by Appleton-Century-Crofts, New York, 1976). In
recent years with an increasing inclination toward cleanliness, a
need continues to exist for the persistent elimination of such an
axillary odor.
[0004] It has been reported in recent years that
3-methyl-2-hexenoic acid (3M2H) is a key odor molecule of apocrine
sweat. This is secreted from apocrine glands in covered formby
apolipoprotein D On the skin surface, this protein is decomposed by
resident skin flora existing, and hence, an odor is generated (for
example, Zeng C., et al., Proc. Natl. Acad. Sci. U.S.A., 93,
6626-6630, 1996).
[0005] There are conventionally-known control techniques for human
body malodors. First, sweat control techniques on antiperspiratory
effects such as zinc paraphenolsulfonate, citric acid, and various
aluminum and zirconiuim salts. Secondly, growth control techniques
against causative microorganisms of human body malodors by
antimicrobial agents such as triclosan and benzalkonium chloride.
Thirdly, techniques for converting lower fatty acids, causative
substances of body odors, into metal salts with zinc white (zinc
oxide) or the like or deodorizing produced body malodors with
substances having deodorizing effects such as flavonoid and
chlorophyll. Finaly, masking techniques by--fragrances of perfumes
or colognes.
[0006] However,--these techniques are not sufficient for reducing
body malodors led by axillary odor. Additionaly, antimicrobial
techniques may have a potential danger of a reduction in the
primary barrier function of the skin, because they also destroy
resident skin flora
[0007] On the other hand, ginkgo has blood flow promoting effects
and anti-inflammatory effects, and Phellodendron Bark has
anti-inflammatory effects and intestinal function regulating
effects. They are hence contained in Chinese herbal remedies,
beverages and the like. It is, however, not known at all that they
have an effect to inhibit body malodors.
[0008] An object of the present invention is to provide a deodorant
agent which is high in safety and can radically inhibit the
occurrence of human body malodors led by sweat odor, especially,
axillary odor.
DISCLOSURE OF THE INVENTION
[0009] The present inventors were interested in the apocrine odor
which is considered to be one of causative substances of human body
malodors, and have proceeded with an investigation about inhibition
of its formation. As a result, it has been found that certain
particular plant extracts have an effect to inhibit the
decomposition of apolipoprotein D, a carrier protein for odor
molecules, by microorganisms resulting in reduction of malodors,
and are useful substances capable of inhibiting the human body
malodors.
[0010] Specifically, the present invention provides a deodorant
agent comprising, as an active ingredient, ginkgo or Phellodendron
Bark or an extract thereof.
[0011] The present invention also provides use of ginkgo or
Phellodendron Bark or an extract thereof for the production of a
deodorant agent.
[0012] The present invention further provides a method for
inhibiting a body malodor, which includes applying ginkgo or
Phellodendron Bark or an extract thereof to the skin.
BRIEF DESCRIPTION OF THE DRAWINGS
[0013] FIG. 1 is a diagram showing decomposition-inhibiting effects
of a ginkgo extract for apolipoprotein D.
[0014] FIG. 2 is a diagram showing body-odor-inhibiting effects of
the ginkgo extract.
[0015] FIG. 3 is a diagram showing decomposition-inhibiting effects
of a Phellodendron Bark extract for apolipoprotein D.
[0016] FIG. 4 is a diagram showing body-odor-inhibiting effects of
the Phellodendron Bark extract.
MODES FOR CARRYING OUT THE INVENTION
[0017] Ginkgo that can be used as a deodorant agent according to
the present invention means Ginkgo biloba L. of the Ginkgoaceae
family, whereas Phellodendron Bark that can be used as a deodorant
agent according to the present invention means Phellodendron
amurens Ruprecht of the Rutaceae family. As ginkgo, its leaves can
be used either without modification or after grinding, with the use
of leaves being preferred. As for Phellodendron Bark, on the other
hand, the use of its bark is preferred.
[0018] The term "extract of ginkgo or Phellodendron Bark" as used
herein means an extract in one of various solvents--which is
obtained, for example, by extracting ginkgo leaves or Phellodendron
Bark at room temperature or elevated temperature or extracting the
same with an extraction apparatus such as Soxhlet extractor--its
dilution, its concentrate, or its dried powder. The extract can be
a mixed extract obtained from two or more plants.
[0019] Examples of the solvent usable for extraction include water;
alcohols such as methanol, ethanol, propanol and butanol; ketones
such as acetone, methyl ethyl ketone; esters such as methyl acetate
and ethyl acetate; linear and cyclic ethers such as tetrahydrofuran
and diethyl ether; halogenated hydrocarbons such as
dichloromethane, chloroform and carbon tetrachloride; hydrocarbons
such as hexane, cyclohexane and petroleum ether; aromatic
hydrocarbons such as benzene and toluene; polyethers such as
polyethylene glycol; pyridines; oils and fats, such as soybean oil,
rapeseed oil, squalane, isopropyl myristate, palmitic acid, oleic
acid, and linoleic acid; and supercritical carbon dioxide. They can
be used either singly or in combination.
[0020] When used singly, low-polarity solvents such as ethanol,
acetone, hexane, oils or fats, and supercritical carbon dioxide are
preferred. When used in combination, on the other hand,
water-alcohol mixed solvents are preferred, with a water-ethanol
mixed solvent being more preferred. The content of ethanol can be
preferably 50 v/v % or higher, more preferably 80 v/v % or higher,
still more preferably 95 v/v % or higher.
[0021] Extraction conditions differ depending on the solvent to be
used. When extracting with a water-ethanol mixed solvent, for
example, it is preferred to use from 70 to 100 mL of the solvent
per 10 of ginkgo or phellodendron bark and to conduct the
extraction at a temperature of from 15 to 35.degree. C., preferably
from 20 to 25.degree. C. for 30 hours to 10 days, preferably for 5
to 8 days.
[0022] The extract can be used after removing inert impurities from
it by a technique such as liquid-liquid partition, and the use of
such an extract is preferred in the present invention. They can
also be used after subjecting them to treatment such as deodorizing
and/or decoloring as needed by method(s) known per se in the
art.
[0023] The ginkgo or Phellodendron Bark extract can be used without
modification as a deodorant agent according to the present
invention. As an alternative, the extract can also be used by
diluting it or by concentrating or lyophilizing it and then
preparing the concentrate or lyophilizate into a powder or
paste-like form.
[0024] Ginkgo or Phellodendron Bark or an extract thereof as
described above inhibits the decomposition of apolipoprotein D by
microorganisms and inhibits the emission of body odors as will be
demonstrated subsequently in examples. It is considered that
causative substances (odor molecules) of human body odors,
primarily the apocrine odor which is a causative odor of axillary
odor are considered to be branched, unsaturated lower fatty acids
typified by 3-methyl-2-hexenoic acid (3M2H), and also that such
odor molecules are included in carrier proteins and secreted into
sweat by apocrine glands and the carrier proteins are then
decomposed and liberated by microorganisms residing on the skin
(Zeng C., et al., Proc. Natl. Acad. Sci. U.S.A., 93, 6626-6630,
1996). As apolipoprotein D is a carrier protein for the odor
molecules, it is considered to be possible to inhibit the
production of body odors if such decomposition of apolipoprotein D
can be inhibited.
[0025] Accordingly, the production of body odors can be inhibited
by applying ginkgo, Phellodendron Bark or an extract thereof to the
skin in accordance with the present invention, and a preparation
with ginkgo, Phellodendron Bark or an extract thereof contained in
an effective amount therein can serve as a deodorant agent which
could eradicate the production of such causative substances of
odors.
[0026] The deodorant agent according to the present invention can
be used as preparations such as cosmetics, external drug products
and quasi-drug products, for example, creams, emulsions, lotions,
powders, sprays, sticks, sheets, and plasters such as poultices. It
is also possible to use two or more application methods in
combination.
[0027] Concerning the content of ginkgo, Phellodendron Bark or an
extract thereof upon using the deodorant agent according to the
present invention as a cosmetic, external drug product or
quasi-drug product, the content of ginkgo or Phellodendron Bark can
be set preferably at from 0.1 to 20 wt % in terms of dry weight
basis in the composition, with from 0.5 to 10 wt % being preferred,
and the content of the ginkgo or Phellodendron Bark extract can be
set preferably at from 0.00001 to 10 wt % in terms of solid content
basis in general, with from 0.0005 to 5 wt % being preferred.
[0028] In addition to various ingredients commonly employed in
these cosmetics, external drug products or quasi-drug products, for
example, those generally used as cosmetic ingredients such as oils,
surfactants, alcohols, chelating agents, pH adjusters,
preservatives, viscosity increasing agents, colorants and
fragrances, other ingredients such as ultraviolet absorbers,
whitening agents, anti-wrinkle agents, humectants, sebum excretion
inhibitors, emollients, keratin protecting agents,
pharmaceutically-active agents, antioxidants and solvents can be
added in a desired combination upon preparation.
[0029] Moreover, the above-described preparations can each be
provided with enhanced deodorant effects by adding finely-divided
powder of a natural or synthesized, porous metal oxide, an
astringent compound including a metal such as aluminum, zirconium
or zinc as a component, a bactericidal agent, an antimicrobial
agent, an antibiotic and/or the like as needed.
[0030] The deodorant agent according to the present invention can
control the production of body odors by applying it to areas where
malodors tend to occur, such as the feet, axillae, head and pubes.
In such applications, the preparation can preferably be applied,
for example, in an amount of from 1 to 20 mg in the case of a
liquid preparation or in an amount of from 1 to 50 mg in the case
of a solid preparation, per cm.sup.2 of the skin, although it
differs depending on the content of the active ingredient.
EXAMPLES
Production Example 1
Preparation of Ginkgo Extract
[0031] To leaves (10 g) of ginkgo (Ginkgo biloba L.), a 95 v/v %
aqueous ethanol solution (85 mL) was added. Subsequent to
extraction at room temperature for 7 days, filtration was conducted
to obtain an extract (yield: 85 mL, evaporation residue: 1.59 w/v
%).
Production Example 2
Preparation of Phellodendron Bark Extract
[0032] To bark (10 g) of Phellodendron Bark (Phellodendron
amurensRuprecht), a 95 v/v % aqueous ethanol solution (85 mL) was
added. Subsequent to extraction at room temperature for 7 days,
filtration was conducted to obtain an extract (yield: 85 mL,
evaporation residue: 0.72 w/v %).
Example 1
Decomposition Inhibiting Effects for Apolipoprotein D
(1) Preparation of Sweat
[0033] Absorbent cotton pads, each of which had been moistened with
distilled water (1.5 mL), were held in the armpits of plural male
subjects, the armpits having had the apocrine odor, and were then
squeezed to collect a solution (57.5 mL). After the solution was
filtered through a 0.45-.mu.m filter, it was concentrated by
"Centriprep YM-10" (Millipor Corporation). Distilled water was
added again, and concentration was likewise conducted by
"Centriprep YM-10" to remove low molecular weight substances. The
thus-prepared solution was provided as a sweat concentrate.
[0034] (2) To the sweat concentrate (0.04 mL) prepared by the
above-described procedure (1), 100 mL Tris-HCl buffer (0.03 mL),
distilled water (0.02 mL) and the ginkgo or Phellodendron Bark
extract (0.1 mL) prepared in Preparation Example 1 and 2 were
added. Brevibacterium epiderumidis which had been washed (three
times) with 20 mL Tris-HCl buffer (pH 7.2) was inoculated to give a
final cell count of about 10.sup.8 cfu/mL, and subsequent to
incubation at 37.degree. C. for 24 hours, antibody staining was
performed. Sodium dodecyl sulfate polyacrylamide electrophoresis
(SDS-PAGE) of the cell-treated sweat concentrate employed "Ready
gel J" (separating gel concentration: 15%, Bio-Rad Laboratories,
Inc.). As the antibody staining, proteins separated by the SDS-PAGE
were electrically transferred from the gel onto a PVDF filter
(Millipor Corporation, "Immobilon Transfer Membrane"), and
apolipoprotein D was detected by "ECL Plus Western Blotting
Detection System" (Amersham Pharmacia Biotech) while using an
anti-apolipoprotein D monoclonal mouse antibody (RDI) as a primary
antibody and an HRP-labeled anti-mouse Ig antibody (Amersham
Pharmacia Biotech) as a secondary antibody, and image processing
was performed, and then, the residual rate of apolipoprotein D
(=the amount of apolipoprotein D in the sample/the amount of
apolipoprotein D in the untreated sweat concentrate.times.100) was
calculated. The results are shown in FIG. 1 and FIG. 3 (in the
diagrams, "ApoD" stands for apolipoprotein D).
[0035] By the Brevibacterium epiderumidis treatment of the sweat
concentrate, the apolipoprotein D in the sweat concentrate was
decomposed and decreased. By the addition of the ginkgo extract or
Phellodendron Bark extract, however, the decomposition of
apolipoprotein D was inhibited.
Example 2
Body Odor Inhibition Test (1)
[0036] A solution, which had been prepared by diluting the ginkgo
extract to 10% concentration with 20% ethanol, was applied to one
axillae of four subjects, and a control (20% ethanol, 0.5 g) was
applied to the other axillae of the subjects, and axillary pads
were worn in their both axillae. After seven hours, they entered an
air-conditioned room of 40.degree. C. and 75% RH and stayed there
for 5 minutes. After eight hours, the axillary pads were collected,
and an olfactory assessment was performed by a panel of three
experts in accordance with the following standards, and the odor
level was determined by an average of their scores. The results are
shown in FIG. 2.
[0037] 5: very strong odor
[0038] 4: strong odor
[0039] 3: moderate odor
[0040] 2: perceivable odor
[0041] 1: weak odor
[0042] 0: no odor
[0043] By the application of the 10% ginkgo extract, the level of
axillary odor of each subject was lowered, and the production of
body odors was inhibited.
Example 3
Body Odor Inhibition Test (2)
[0044] The Phellodendron Bark extract prepared in Production
Example 2 was concentrated to dryness, and then added to the
ingredients shown below in Table 1 to give a solid content of 0.2%.
Subsequently, a deodorant agent (stick) was prepared. By a similar
method as in Example 2, its body odor inhibition effects were
assessed. The results are shown in FIG. 4. TABLE-US-00001 TABLE 1
<Stick> Ingredients % w/w Aluminum zirconium
tetrachlorohydrate glycine 24.0 Cyclomethicone 54.8 Stearyl alcohol
15.0 Hydrogenated castor oil 5.0 Silica 1.0 Phellodendron Bark
extract 0.2 Total 100.0
[0045] By the application of the 0.2% Phellodendron Bark extract,
the level of axillary odor of each subject was lowered, and the
production of body odors was inhibited.
INDUSTRIAL APPLICABILITY
[0046] The deodorant agent according to the present invention can
persistently inhibit the emission of human body malodors, and
therefore, is useful as a material having excellent deodorizing
effects and high safety.
* * * * *